Video
Author(s):
Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.
Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset
FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis
Subcutaneous Dacogen Elicits Responses Among Some With Myelofibrosis
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
Empowering Patients With Cancer Through Clear Clinical Trial Communication
Ryoncil Receives FDA Approval for Children With GVHD